Therapeutic effects pharmacokinetics recombinant human granulocyte-macrophage colony-stimulating factor childhood cancer patients myelosuppressive chemotherapy Twenty-five children refractory solid tumors recombinant human granulocyte-macrophage colony-stimulating factor rhGM-CSF escalated doses intravenous infusions hours myelosuppressive treatment cisplatin etoposide Tolerance rhGM-CSF exceptional dose levels maximum-tolerated dosage MTD adults agent dose-related increases platelet neutrophil counts durations severe neutropenia thrombocytopenia analysis dosages equal treatment rhGM-CSF median number days antibiotic therapy fever neutropenia half rhGM-CSF leukopenic children doses high MTD study ability growth factor severe neutropenia thrombocytopenia important role management childhood solid tumors 